Skip to main content
    M

    Marker Therapeutics Inc (MRKR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.89
    -0.00 (-0.30%)

    Market Cap: $14.93M

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(20/32)
    Avg Surprise
    -8.00%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.16 - $-0.12
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.18+24.3%
    60d ago$-0.140.0%
    30d ago$-0.140.0%
    7d ago$-0.140.0%
    Current$-0.14
    Revenue Consensus
    $2M
    Range$700000 - $4M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.06
    Range$-0.12 - $0.01
    2 analysts
    Revenue Consensus
    $762670
    Range$-679330 - $2M
    3 analysts
    Last 12 of 39 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.06$-0.12 - $0.01--2--
    Sep 26EST
    		-$-0.14$-0.16 - $-0.12--2
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 14
    		$-0.09N/A-+64.00%Beat2
    1
    0
    30d
    		+69.0%
    Mar 26
    Reported May 15
    		$-0.16$-0.19$-0.19 - $-0.19+15.79%Beat1
    No revisions (30d)
    		+60.0%
    Dec 25
    Reported Mar 18
    		$-0.04N/A-+78.95%Beat2
    1
    0
    30d
    		+90.5%
    Sep 25
    Reported Nov 13
    		$-0.12$-0.21$-0.21 - $-0.21+42.86%Beat1
    No revisions (30d)
    		+53.8%
    Jun 25
    Reported Aug 14
    		$-0.29$-0.27$-0.27 - $-0.27-7.41%Miss1
    No revisions (30d)
    		-16.0%
    Mar 25
    Reported May 21
    		$-0.40$-0.66$-0.66 - $-0.66+39.39%Beat0
    No revisions (30d)
    		-48.1%
    Dec 24
    Reported Mar 31
    		$-0.42$-0.22$-0.28 - $-0.16-90.91%Miss2
    0
    1
    30d
    		+12.5%
    Sep 24
    Reported Nov 14
    		$-0.26$-0.39$-0.39 - $-0.39+33.33%Beat1
    1
    0
    30d
    		+23.1%
    Jun 24
    Reported Aug 14
    		$-0.25$-0.43$-0.43 - $-0.43+41.86%Beat1
    No revisions (30d)
    		-187.4%
    Mar 24
    Reported May 15
    		$-0.27$-0.25--8.00%Miss--+52.6%
    Dec 23
    Reported Mar 26
    		$-0.48N/A-+52.00%Beat0
    No revisions (30d)
    		+85.3%
    Sep 23
    Reported Nov 9
    		$-0.34N/A-N/ABeat--+57.8%

    Key Metrics

    Valuation
    P/E Ratio-2.18EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-245.50%Operating Margin-267.90%
    ROE-76.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.03xQuick Ratio6.03x
    Trading Statistics
    Beta1.62Avg Volume191.24K
    52-Week High$2.4652-Week Low$0.84

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.95
    SMA 20$0.99
    SMA 50$1.09
    SMA 200$1.34
    EMA 10$0.96
    EMA 20$0.99
    EMA 50$1.07
    EMA 200$1.25

    MACD

    Line: -0.04Signal: -0.04Hist: -0.00

    ADX

    ADX: 19.8+DI: 17.6-DI: 27.1

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down64.0
    PSAR$1.20

    Bollinger Bands

    Upper Band$1.17
    Lower Band$0.81
    %B Position3674%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    41.2

    Momentum Oscillators

    Stoch %K15.6
    Stoch %D20.8
    Williams %R-94.5
    ROC (10d)-7.0%
    Momentum-0.07
    CCI (20d)-89.4
    MFI (14d)47.5

    Volatility Measures

    ATR (14d)$0.11(11.9%)
    StdDev (20d)0.09
    Hist Vol117.7%(High)

    Volume Flow

    VWAP$0.91
    OBV15.6M
    AD Line-93.1M
    CMF (20d)-0.281

    Volume Metrics

    Avg Vol (20d)200.7K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.03

    Pivot Points

    R3$1.14
    R2$1.09
    R1$0.99
    Pivot Point$0.94
    S1$0.84
    S2$0.79
    S3$0.69

    Advanced Oscillators

    TSI-12.22
    Ultimate Osc30.3
    KST-99.86

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$1.10M$1.23M$0$0$2.25M$1.93M$1.17M$1.24M$1.06M$257,606
    Cost of Revenue$0$0N/A$0$0$0$5.09M$0$0$0$2.62M$0
    Gross Profit$0$0$1.10M$1.23M$0$0$2.25M$1.93M$1.17M$1.24M$1.06M$257,606
    Operating Expenses$2.62M$4.07M$2.99M$3.37M$5.12M$4.96M$6.11M$4.33M$3.48M$3.79M$3.99M$3.46M
    R&D$1.48M$2.84M$2.14M$2.35M$4.18M$3.14M$5.09M$3.47M$2.34M$2.58M$2.62M$2.04M
    SG&A$1.14M$1.23M$846,607$1.02M$945,163$1.37M$1.03M$854,677$1.14M$1.22M$1.38M$1.41M
    Operating Income$-2,620,366$-4,072,535$-1,883,994$-2,136,726$-5,122,217$-4,957,777$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    Interest Income$112,558$132,889$165,628$138,064$128,025$162,489$73,746$91,681$115,388$156,195$201,339$218,085
    Interest Expense$0$0$4.16M$0$0$0$0$0$0$0$0$0
    Income Before Tax$-1,826,229$-3,187,955$-6,047,106$-1,998,662$-4,133,008$-4,446,184$-3,787,671$-2,308,192$-2,192,677$-2,392,822$-2,736,454$-2,981,961
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,826,229$-3,179,278$-1,703,210$-1,998,662$-4,015,564$-4,446,184$-3,837,624$-2,308,192$-2,192,677$-2,392,822$-2,803,066$-2,981,961
    EBITDA$-1,938,787$-3,320,844$-1,883,994$-2,136,726$-4,261,033$-4,608,673$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    EBIT$-1,938,787$-3,320,844$-1,883,994$-2,136,726$-4,261,033$-4,608,673$-3,861,417$-2,399,873$-2,308,065$-2,549,017$-2,937,793$-3,200,046
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MRKR

    News

    Marker Therapeutics, Inc. Estimates – NASDAQ:MRKR

    This article provides an overview of Marker Therapeutics, Inc. (NASDAQ: MRKR) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various...

    TradingView•10/23/26•Neutral

    Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

    Marker Therapeutics, Inc. has been awarded a $2.6 million Orphan Products Development Grant by the FDA to support the clinical development of its multi-antigen T cell product, MT-601...

    Moomoo•10/20/26•Bullish

    Marker Therapeutics receives $2.6M FDA grant for cancer study

    Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 clinical study of MT-601 for locally advanced unresectable pancreatic cancer. This...

    Investing.com•10/19/26•Bullish

    The FDA chose six projects from 66 applications. Marker gets $2.6 million for a planned pancreatic cancer study.

    Marker Therapeutics (MRKR) has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its MT-601 therapy for pancreatic cancer. This non-dilutive funding will support a Phase...

    Stock Titan•10/19/26•Bullish

    Marker Therapeutics receives $2.6M FDA grant for cancer study By Investing.com

    Marker Therapeutics Inc. has been awarded a $2.6 million grant from the FDA to support a Phase 1 clinical study of MT-601, its multi-antigen recognizing T cell therapy...

    Investing.com UK•10/19/26•Bullish

    MRKR Valuation and Fair Value

    P/E
    -2.2x
    P/B
    1.4x
    See GNG's fair value

    MRKR Profitability: Margins, ROIC and FCF

    Operating margin
    -267.9%
    Net margin
    -245.5%
    ROE
    -76.9%

    MRKR Competitors

    CompanyTicker
    Neuphoria Therapeutics IncNEUP
    MDxHealth SAMDXH
    Citius Pharmaceuticals IncCTXR
    Cytosorbents CrpCTSO
    HeartSciences Inc.HSCS
    Tscan Therapeutics IncTCRX
    Cyclerion Therapeutics IncCYCN
    Biocardia IncBCDA

    Sector: Healthcare

    MRKR Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    0
    Buy
    3
    Hold
    0
    Sell
    0
    Strong Sell
    0

    MRKR Bull Case vs Bear Case

    Bull case

    • MRKR beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • MRKR has a -245.5% net profit margin.
    • MRKR's quarterly revenue changed -51.0% year over year.

    MRKR Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    22.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    MRKR Earnings Date

    MRKR reports Nov 11, 2026. The date is estimated.

    MRKR ETF Holders

    GNG tracks 3 ETFs that hold MRKR. The largest weights:

    1. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    3. Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund
    Open the ETF Stock Exposure tool for MRKR

    See insider activity

    Frequently Asked Questions About MRKR

    When does MRKR report earnings?

    Marker Therapeutics Inc (MRKR) is expected to report earnings on Nov 11, 2026.

    Does MRKR pay dividends?

    Marker Therapeutics Inc (MRKR) does not currently pay a regular dividend.

    What is MRKR's market cap?

    Marker Therapeutics Inc (MRKR) has a market capitalization of $14.93M with a current stock price of $0.89.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In